SAR443820 + erythromycin ethyl succinate

SAR443820 + erythromycin ethyl succinate is a combination of two drugs: **SAR443820**, a selective, orally bioavailable, central nervous system-penetrant small molecule inhibitor of receptor-interacting serine/threonine-protein kinase 1 (RIPK1), and **erythromycin ethyl succinate**, a macrolide antibiotic. SAR443820 works by inhibiting RIPK1, a critical signaling protein in the TNF receptor pathway, modulating inflammation and cell death in tissues throughout the body and central nervous system. By inhibiting RIPK1, SAR443820 reduces neuroinflammation and neuronal cell death and is being studied primarily for neurodegenerative diseases[1][2][3][5]. Erythromycin ethyl succinate acts by binding to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis and thus bacterial growth; it is indicated for a broad range of bacterial infections. As an investigational combination, there is no evidence that SAR443820 + erythromycin ethyl succinate is an established or clinically tested fixed combination; their combination here is descriptive of these two individual drugs being administered together, each with distinct mechanisms of action.